Literature DB >> 9191545

Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein.

C Jansson1, C Boguszewski, S Rosberg, L Carlsson, K Albertsson-Wikland.   

Abstract

The impact of the adoption of the new biosynthetic growth hormone (GH) WHO International Reference Preparation (IRP 88/624), and the recommendation to report results in microgram/L instead of mU/L, is described. Conversion factors were determined by comparing both the linear and nonlinear relations of the GH values. The Pharmacia polyclonal IRMA (p-IRMA) and the DELFIA monoclonal time-resolved immunofluorometric assay (trIFMA) with kit calibrators calibrated either against the pituitary-derived WHO IRP 80/505 or the new 88/624 were evaluated. Conversion factors of 4.17 mU/L = 1 microgram/L for the p-IRMA and 4.31 mU/L = 1 microgram/L for the trIFMA were necessary. Different cross-reactivity patterns for the deaminated and dimer 22-kDa, 20-kDa, and 17-kDa GH isoforms were found. Expected GH recovery was similar when the measured values were adjusted according to the results of the cross-reactivity study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9191545

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

Review 1.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Seasonal variations in vitamin D in relation to growth in short prepubertal children before and during first year growth hormone treatment.

Authors:  B Andersson; D Swolin-Eide; B Kriström; L Gelander; P Magnusson; K Albertsson-Wikland
Journal:  J Endocrinol Invest       Date:  2015-08-09       Impact factor: 4.256

Review 3.  Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Authors:  Martin Bidlingmaier; Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

4.  Interpretation of hormone levels in older patients: points for consideration.

Authors:  Krystyna Sztefko; Patrycja Szybowska
Journal:  Int J Endocrinol       Date:  2012-05-14       Impact factor: 3.257

Review 5.  Provocative growth hormone testing in children: how did we get here and where do we go now?

Authors:  Camilia Kamoun; Colin Patrick Hawkes; Adda Grimberg
Journal:  J Pediatr Endocrinol Metab       Date:  2021-04-12       Impact factor: 1.520

Review 6.  Growth hormone variants: a potential avenue for a better diagnostic characterization of growth hormone deficiency in children.

Authors:  A E Rigamonti; M Bozzola; G Banfi; C Meazza; E E Müller; S G Cella
Journal:  J Endocrinol Invest       Date:  2012-10-01       Impact factor: 5.467

7.  Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children.

Authors:  Björn Andersson; Gunnel Hellgren; Andreas F M Nierop; Ze'ev Hochberg; Kerstin Albertsson-Wikland
Journal:  Proteome Sci       Date:  2009-11-02       Impact factor: 2.480

Review 8.  Growth hormone assays: current methodologies and their limitations.

Authors:  Martin Bidlingmaier; Christian J Strasburger
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

9.  The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children.

Authors:  Berit Kriström; Jovanna Dahlgren; Aimon Niklasson; Andreas F M Nierop; Kerstin Albertsson-Wikland
Journal:  BMC Med Inform Decis Mak       Date:  2009-01-12       Impact factor: 2.796

10.  Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age.

Authors:  Jovanna Dahlgren; Berit Kriström; Aimon Niklasson; Andreas F M Nierop; Sten Rosberg; Kerstin Albertsson-Wikland
Journal:  BMC Med Inform Decis Mak       Date:  2007-12-12       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.